The DTWD1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from human HT29 colorectal adenocarcinoma cells. This product features targeted disruption of the DTWD1 gene, which encodes a predicted tRNA modification enzyme. The polyclonal pool contains heterogeneous loss-of-function edits, providing a robust model to study DTWD1 depletion without clonal selection biases. This knockout resource supports investigations into tRNA biology in cancer and other cellular processes.
The parental HT29 cell line is a widely used model of human colorectal adenocarcinoma, originally derived from a 44-year-old female. These epithelial cells are employed in studies of colon cancer proliferation, differentiation, drug sensitivity, and signaling. HT29 cells express intestinal epithelial markers and are suitable for both in vitro assays and xenograft models. As a host for DTWD1 knockout, they offer a physiologically relevant context for examining tRNA modification in colorectal malignancy.
DTWD1 is predicted to act within the tRNA modification machinery, likely as a subunit of a multiprotein complex that installs chemical modifications on tRNA molecules. These modifications are critical for translation fidelity by ensuring proper codon?Canticodon interactions. Although DTWD1??s exact biochemical role and interacting partners remain undefined, its loss is expected to compromise the tRNA modification landscape, potentially leading to altered protein synthesis and disrupted cellular homeostasis.
In HT29 colorectal adenocarcinoma cells, DTWD1 knockout enables dissection of the relationship between tRNA processing defects and malignant behavior. Aberrant translation is a cancer hallmark, and dysregulated tRNA modification may contribute to tumor progression and drug resistance. This polyclonal knockout model allows researchers to investigate how DTWD1 loss influences HT29 proliferation, colony formation, migration, and invasion, as well as changes in chemosensitivity linked to translational control.
Applications include proliferation and colony formation assays to assess growth, migration/invasion assays for metastatic potential, and molecular analyses such as RNA-seq, western blotting, and tRNA modification profiling. This polyclonal knockout resource is particularly valuable for functional genomics studies, drug sensitivity screens, and exploring tRNA biology in colorectal cancer, all within a heterogeneous cell population that mirrors tumor cellular diversity. For further information, please contact Ascent Research.
